-
Phase 1
-
-
18+Age Range
-
19Locations
-
Recruiting
Menu
Thank you for submitting your question. You will get a reply within two business days to the email you provided. Thank you.
Recruiting
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
Inclusion Criteria: - Must have histologically or cytologically confirmed adenocarcinoma of the prostate - Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC) - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 Exclusion Criteria: - Prior treatment with an androgen receptor (AR) degrader - Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of IP - Clinically significant venous thromboembolism within 3 months prior to the first dose of IP - Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness Other protocol-defined inclusion/exclusion criteria apply
Study Arms
Experimental: Administration of CC-94676, CC1083611, and CC1083610